LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

0.42 7.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.38

Max

0.44

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+1420% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-449M 98M
Eelmine avamishind	-7.27
Eelmine sulgemishind	0.42

Uudiste sentiment

By Acuity

96%

333 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. veebr 2026, 23:53 UTC

Kuumad aktsiad

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27. veebr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27. veebr 2026, 17:55 UTC

Kuumad aktsiad

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27. veebr 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27. veebr 2026, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

27. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 21:30 UTC

Tulu

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27. veebr 2026, 21:30 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27. veebr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27. veebr 2026, 21:17 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 21:10 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27. veebr 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27. veebr 2026, 21:00 UTC

Tulu

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27. veebr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27. veebr 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27. veebr 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27. veebr 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27. veebr 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27. veebr 2026, 19:39 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 19:38 UTC

Tulu

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27. veebr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27. veebr 2026, 18:45 UTC

Tulu

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27. veebr 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 17:07 UTC

Tulu

Pemex Cuts 4Q Loss As Operating Results Improve

27. veebr 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27. veebr 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27. veebr 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27. veebr 2026, 15:49 UTC

Tulu

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

1420% tõus

12 kuu keskmine prognoos

Keskmine 6.08 USD 1420%

Kõrge 15 USD

Madal 0.5 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

333 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.